Founded in 2020 and based in Munich and Boston, mbiomics GmbH is a private biotech company focused on the development of a new generation of complex live bacterial therapeutics (LBT). By combining proprietary precision analysis and patient insights, mbiomics is building a pipeline of rationally selected microbial communities to achieve indication-specific treatment and accommodate patient heterogeneity. The goal of mbiomics is to access the full immunological and metabolic potential of the gut microbiome to restore healthy microbial ecosystems and thus overcome disease.
The founders of mbiomics have established a proprietary fluorescence microscopy-based profiling technology (Woehrstein et al., Science Advances, 2017) with a combination of optimised precision, sensitivity, taxonomic depth, and quantification properties. The mbiomics multiplex panels decipher the microbial composition of a human sample quickly, accurately and simultaneously. These data are critical to better support the selection of optimal bacterial strains for complex consortia with tailored disease-specific characteristics and a superior efficacy and safety profile. In addition, mbiomics' core technology also improves patient selection and monitoring for clinical trials, creating a competitive advantage for pharmaceutical companies.